A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Trial Profile

A phase 3b, double-blind, multicenter, randomized study to compare the efficacy and safety of single dose dalbavancin to a two dose regimen of dalbavancin for the treatment of acute bacterial skin and skin structure infections

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data fro four phase III stuadies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 30 Oct 2016 Pooled results of this and other 3 trial (VER001-9, DUR001-301 and DUR001-302 presented at the IDWeek 2016
    • 12 Apr 2016 Results comparing patients treated in the outpatient setting with patients admitted to a hospital presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top